Xvivo Perfusion AB (publ), a medical technology enterprise based in Gothenburg, Sweden, specializes in developing cutting-edge solutions for the preservation and perfusion of organs, tissues, and cells, crucial for transplantation. The company's reach spans diverse global markets, including Sweden, the United States, broader North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its extensive product lineup features the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system engineered for secure normothermic ex vivo lung perfusion (EVLP). This is supported by the XPS Disposable Lung Kit, which supplies all necessary sterile consumables. Xvivo Perfusion also provides STEEN Solution, a uniquely formulated buffered extracellular solution for perfusing isolated donor lungs during EVLP procedures. Further offerings include Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte preservation solution; the XVIVO Silicone Tubing Set for rapid flushing of donor lungs during the procurement phase; and both the XVIVO LS and XVIVO Disposable Lung Set, specialized devices for EVLP. Additionally, the company offers the XVIVO Organ Chamber, a single-use sterile container designed for the temporary holding of isolated lungs before transplantation into a recipient, alongside the XVIVO Lung Cannula Set, another sterile, single-use disposable product. The company was founded in 1998.
The current price of XVIPY is $6.33 USD — it has increased by +0% in the past 24 hours. Watch Xvivo Perfusion AB stock price performance more closely on the chart.
What is Xvivo Perfusion AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Xvivo Perfusion AB stocks are traded under the ticker XVIPY.
What is Xvivo Perfusion AB market cap?▼
Today Xvivo Perfusion AB has the market capitalization of 199.39M
When is the next Xvivo Perfusion AB earnings date?▼
Xvivo Perfusion AB is going to release the next earnings report on October 22, 2026.
What were Xvivo Perfusion AB earnings last quarter?▼
XVIPY earnings for the last quarter are 0.07 USD per share, whereas the estimation was 0.08 USD resulting in a -13.76% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Xvivo Perfusion AB revenue for the last year?▼
Xvivo Perfusion AB revenue for the last year amounts to 85.26M USD.
What is Xvivo Perfusion AB net income for the last year?▼
XVIPY net income for the last year is 2.82M USD.
How many employees does Xvivo Perfusion AB have?▼
As of July 23, 2026, the company has 170 employees.
In which sector is Xvivo Perfusion AB located?▼
Xvivo Perfusion AB operates in the Other sector.
When did Xvivo Perfusion AB complete a stock split?▼
Xvivo Perfusion AB has not had any recent stock splits.
Where is Xvivo Perfusion AB headquartered?▼
Xvivo Perfusion AB is headquartered in Mölndal, United States.